Back

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Recent advances in diagnosis/treatment of hypertension Target Organ Damage/Left Ventricular Hypertrophy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Peter Kolkhof

BAYER AG, R&D Pharmaceuticals, Wuppertal (Germany)

3 More presentations in this session

Presentation thumbnail
Potential therapeutic efficacy via avB3-integrin dependent interaction of developmental endothelial locus-1 (Del-1) after established angiotensin-II dependent hypertension
Mr M. Amponsah-Offeh (Mannheim, DE)
Abstract Slides Video
Presentation thumbnail
Protective effects of renal denervation based on MRI assessment of the brain in patients with resistant hypertension
Doctor A. Sukhareva (Tomsk, RU)
Abstract Slides Video
Presentation thumbnail
24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension
Associate Professor D. Maximkin (Moscow, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Recent advances in diagnosis/treatment of hypertension

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
How does imaging guide management in my patients with hypertension?
thumbnail
Congress Presentation
Arterial hypertension
thumbnail
Congress Presentation
Left ventricular hypertrophy, wall thickness, and histological myocyte alteration in end-stage heart failure: a call for a standard definition

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources